STOCK TITAN
  1. Home
  2. News
  3. OCUL

Ocular Therapeutix Inc - OCUL STOCK NEWS

Welcome to our dedicated news page for Ocular Therapeutix (Ticker: OCUL), a resource for investors and traders seeking the latest updates and insights on Ocular Therapeutix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ocular Therapeutix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ocular Therapeutix's position in the market.

News
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Rhea-AI Summary
Ocular Therapeutix™ announces positive topline Phase 1 data for AXPAXLI™ in diabetic retinopathy, with 46.2% of patients showing improvement in the Diabetic Retinopathy Severity Scale at 40 weeks. AXPAXLI was well-tolerated with no inflammation observed. The company plans to move directly to a Phase 3 study based on the results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.69%
Tags
clinical trial
-
News
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
Rhea-AI Summary
Ocular Therapeutix strengthens its clinical team by appointing key retinal leaders, including Dr. Nadia K. Waheed as Chief Medical Officer and Dr. Peter K. Kaiser as Chief Development Officer. The company aims to advance its Phase 3 AXPAXLI program for wet AMD and diabetic retinopathy, positioning itself as a leading retina care company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
management
-
News
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) announced that Executive Chairman, Pravin U. Dugel, MD, is taking over as President and CEO, with Antony Mattessich stepping down. Dr. Dugel will also continue as a director and Executive Chairman. The company expressed gratitude for Mattessich's service and highlighted the potential of their innovative retinal disease pipeline, particularly AXPAXLI™.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
none
News
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) granted inducement equity awards to its new Senior Vice President, Global Head of Biometrics. The awards include a stock option for 130,000 shares and a restricted stock unit award for 43,333 shares. The awards are part of Ocular's 2019 Inducement Stock Incentive Plan and are subject to specific vesting schedules.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
none
-
News
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Rhea-AI Summary
Ocular Therapeutix, Inc. announces positive Phase 2 data for PAXTRAVA implant in patients with open-angle glaucoma or ocular hypertension. The data show consistent and sustained reductions in Intraocular Pressure (IOP) over six months, with a 24-30% reduction achieved. The implant was well-tolerated, with no impact on corneal health observed. The results indicate potential for repeat dosing without stacking of implants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Ocular Therapeutix™ To Present Data at the 2024 ASCRS Annual Meeting (American Society of Cataract and Refractive Surgery)
Rhea-AI Summary
Ocular Therapeutix, Inc. announces multiple scientific presentations at the 2024 ASCRS Annual Meeting. The presentations focus on innovative therapies for eye diseases like wet AMD and diabetic retinopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.23%
Tags
conferences
News
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
Rhea-AI Summary
Ocular Therapeutix, Inc. reports financial results, leadership appointments, and upcoming milestones. The company aims to be a leader in retinal care with a focus on wet AMD, diabetic retinopathy, and glaucoma treatments. Positive milestones include successful financings, key leadership appointments, and progress in clinical trials. Financially, the company has a strong cash position and increasing revenues. However, there are concerns regarding rising research and development expenses, net losses, and non-cash charges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
earnings
-
News
Ocular Therapeutix™ to Release Fourth Quarter and Full Year 2023 Results on March 11, 2024
Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) plans to report its fourth quarter and full year 2023 financial results on March 11, 2024, after 4:00 p.m. Eastern Time. The company will not host a conference call due to recent leadership appointments and a $325 million private placement. A conference call to discuss corporate strategy is scheduled for the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
earnings
-
News
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Chairman and Chief Strategy Officer
Rhea-AI Summary
Ocular Therapeutix, Inc. (OCUL) grants inducement equity awards to Executive Chairman and Chief Strategy Officer, Dr. Pravin U. Dugel and Dr. Sanjay Nayak. The awards include stock options and restricted stock units, with vesting schedules over multiple years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
none
News
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
Rhea-AI Summary
Ocular Therapeutix, Inc. announces a private placement to raise $325.0 million through the sale of common stock and pre-funded warrants to institutional accredited investors. The funds will be used to accelerate the clinical development of AXPAXLI™ for wet AMD treatment, support other clinical programs, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.99%
Tags
none
Stock OCUL logo
Ocular Therapeutix Inc

Nasdaq:OCUL

OCUL Rankings

#2761 Ranked by Market Cap
#4005 Ranked by Stock Gains
N/A Ranked by Dividends

OCUL Stock Data

1.19B
128.47M
3.68%
50.09%
7.94%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Bedford

About OCUL

ocular therapeutix, inc. is a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel-based formulation technology. ocular therapeutix’s lead product candidate, dextenza™ (dexamethasone insert) 0.4 mg for intracanalicular use, has completed phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. otx-tp (travoprost insert) is in phase 3 clinical development for the reduction of intraocular pressure in patients with glaucoma and ocular hypertension. the company’s earlier stage assets include otx-tic, a sustained release travoprost intracameral injection for the reduction in intraocular pressure in patients with glaucoma and ocular hypertension, as well as sustained release intravitreal injections for the treatment of retinal diseases. these injections include the development of otx-tki, a tyrosine kinase inhib